Trial Profile
A Prospective Observational Study of Safety and Occurrence of Influenza-like Illness Following Administration of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Mar 2017
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions
- Sponsors Novartis
- 04 Oct 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 03 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.